CN104208045A - Compound inhalation preparation containing penicillin antibiotic and glucocorticoid - Google Patents
Compound inhalation preparation containing penicillin antibiotic and glucocorticoid Download PDFInfo
- Publication number
- CN104208045A CN104208045A CN201310205574.8A CN201310205574A CN104208045A CN 104208045 A CN104208045 A CN 104208045A CN 201310205574 A CN201310205574 A CN 201310205574A CN 104208045 A CN104208045 A CN 104208045A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- penicillin
- glucocorticoid
- medicine
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a compound inhalation preparation containing penicillin antibiotic and glucocorticoid and applications thereof. The preparation is capable of treating pulmonary bacterial infection with less dosage and has a certain curative effect on asthma and chronic obstructive pneumonia. The preparation is made into an dry powder inhalation dosage form, after a long period of preservation, the content of allergic matters namely penicilloic acid and penicillenic acid is not increased, so that the happening rate of allergy is largely reduced, when the preparation is used to treat asthma caused by non-microbial infection and chronic obstructive pneumonia.
Description
Technical field:
The present invention relates to a kind of suction preparation and purposes of the compound recipe containing Penicillin antibiotics, glucocorticoid.
Background technology:
Asthma, chronic obstructive pneumonia all belong to the flow limitation disease that respiratory inflammation causes, in recent years along with the impact of smoking, air, anaphylactogen increase etc., sickness rate improves year by year, above-mentioned disease number of patients is many, mortality rate is high, social economical burden weight, has become the important public health problem affecting human health.The treatment of current treatment asthma, chronic obstructive pneumonia is mainly based on inhalant, and compound medicine is then main based on glucocorticoid, epinephrine broxaterol.Also do not find at present anti-bacterial drug especially Penicillin antibiotics treatment non-microorganism infect cause asthma, use in chronic obstructive pneumonia.
Glucocorticoid has antiinflammatory, antiallergic, rheumatism, immunosuppressive action, is widely used in treatment anaphylaxis and auto-immune inflammatory disease.As connective tissue disease, activeness rheumatism, rheumatoid arthritis, lupus erythematosus, serious bronchial asthma, serious dermatitis, ulcerative colitis, acute leukemia etc., also for some severe infections and Comprehensive Treatment that is poisoning, malignant lymphoma.
China's document " inhaled corticosteroids generation is learned and pharmacodynamics " (Wang Changzheng, practical hospital clinical magazine, volume the 1st phase January the 4th in 2007,16-18) point out, suck the first-line drug that parahormone (ICS) has become asthma long-term treatment, as ciclesonide, fluticasone propionate, momestasone furoate, budesonide etc.The document is also pointed out, desirable ICS should be the perfect adaptation of effectiveness and safety, although ICS has huge progress compared with systemic hormonal in the safety for the treatment of, still can not meet the needs of clinical treatment well.Long-term, high-dose uses ICS still to there will be the untoward reaction such as adrenal cortex function suppression, and the ICS (secondary heavy dose) being used alone so-called safe dose can't control severe asthma in majority effectively.
Penicillin antibiotics is the antibiotic that a class contains beta-lactam structure, is divided into semisynthetic penicillin, natural penicillin.Natural penicillin raises from penicillium culture fluid, containing G, K, X, F and two hydrogen F etc.Semisynthetic penicillin on intermediate 6-aminopenicillanic acid (6-APA) side chain, adds different group obtain.
The main route of administration of Penicillin antibiotics medicine is oral or injection, the disease that also can will be caused by atomization inspiration treatment pulmonary bacterial, but there is comparatively significantly shortcoming in this Neulized inhalation, first be that Neulized inhalation needs the long period, and Penicillin antibiotics is longer for standing time in water, the appearance of allergin penicilloic acid and Penicillenic acid. can be increased.The former can be grouped to penicilloic acid polymer, becomes penicilloic acid albumen with polypeptide or protein bound, is the anaphylactogen that a kind of speed is sent out, and is to produce the topmost reason of anaphylaxis, the latter also can form Delayed onset sensitinogen-Penicillenic acid. albumen with cysteine in body, relevant with serum sickness like response, irritated possibility is there is by significantly improving user, next is that the fog sprayed has certain pressure, oral cavity surrounding air is stoped to enter respiratory tract, make suction gas partial pressure of oxygen lower, 3rd is asthma, Patients with Chronic Obstructive Pulmonary Disease pulmonary function is poor, and the mist low temperature of Ultrasonic atomising taring is low, small airway spasm is easily caused after suction, patient is occurred, and breast is vexed, dyspnea symptom, 4th is diameter of aspirin particle precise control after atomization, high amount of drug is at face, the site deposition such as oral mucosa, in bronchus, the target site depositions such as pulmonary are less, untoward reaction is caused to increase, drug availability is less, easy decomposition, curative effect is poor, 5th is use inconvenience, major part medicine has poor taste, patient's is suitable poor by property, so in daily treatment antibacterial medicine especially Penicillin antibiotics generally do not adopt Neulized inhalation.
Bibliographical information (azithromycin combination with glucocorticoids treatment mycoplasma pneumonia observation of curative effect, Hebei medicine in July, 2012, 2182) azithromycin combination with glucocorticoids obtains good clinical effectiveness, but intravenous injection two kinds of medicines adopt intravenous drip mode, use and comparatively bother, process of benefiting from is longer, patient's is suitable poor by property, if use azithromycin simultaneously, glucocorticoid is injected in same container, the problem of existence and stability, the more important thing is that the pharmacological action of penicillin medicine and the azithromycin mentioned in the present invention is completely different, penicillin medicine generates performance antibacterial action mainly through the cell wall of anti-bacteria, azithromycin is then macrolide antibiotics, antibacterial action is played by the synthesis of anti-bacteria RNA.
The warning of food and drug administration's issue on March 12nd, 2013 in addition, now widely used antibiosis is claimed to have the risk of cardiac trigger disease, continuous service time can not more than 6 days according to description azithromycin, and asthma belongs to chronic disease, need long-time medication, so azithromycin is unsuitable for being used for the treatment of asthma and chronic backup pneumonia.
Summary of the invention:
We make inhalant at surprised discovery Penicillin antibiotics, can with lower dosage treatment pulmonary bacterial, simultaneously to asthma, chronic obstructive pneumonia also has certain therapeutic effect, especially after Foradil Aerolizer formoterol fumarate, the content of allergin penicilloic acid and Penicillenic acid. does not improve through long-term placement, and infect in Inhalation in Treating pulmonary bacterial or treatment non-microorganism the asthma caused, during chronic obstructive pneumonia, there is irritated probability greatly to reduce, after we estimate to make Foradil Aerolizer formoterol fumarate with Penicillin antibiotics on the one hand, being sucked into dry powder in pulmonary processes may be more stable, not too easily be decomposed into allergin penicilloic acid and Penicillenic acid., after making inhalant on the other hand, using dosage obviously declines, allergin penicilloic acid and Penicillenic acid. total amount decline obviously, two aspect combineds effect thus reach make the irritated probability occurred greatly decline.
A kind of inhalable drug compositions, is characterized in that the pharmaceutic adjuvant being applicable to inhalation as active component and one or more by a kind of Penicillin antibiotics, a kind of glucocorticoid forms.
Described Penicillin antibiotics is one or more in penicillin (G), procaine benzylpenicillin, benzathine benzylpenicillin, penicillin V (penicillin Vl phenoxymethylpenicillin), oxazacillin, cloxacillin, ampicillin, amoxicillin, piperacillin, azlocillin, mezlocillin, aspoxicillin and pharmaceutically useful salt thereof, and described pharmaceutically useful salt is the one in sodium salt, potassium salt.
Described glucocorticoid is one or more in ciclesonide, fluticasone, mometasone, budesonide, beclometasone, triamcinolone acetonide, methylprednisolone, triamcinolone, hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone or its ester, salt, is preferably one or more in ciclesonide, fluticasone, mometasone, budesonide, beclometasone, triamcinolone acetonide or its ester, salt.The ester of described glucocorticoid is the one in acetate, propionic ester, furoate.The salt of described glucocorticoid is the one in sodium ascorbyl phosphate, acetic acid sodium salt, succinic acid sodium salt.
Described pharmaceutical composition is Foradil Aerolizer formoterol fumarate or aerosol.
The D90 particle diameter of described active component is 1 ~ 10 μm, is preferably 1-7 μm, is more preferably 4 ~ 6 μm.
Described pharmaceutical composition is that the pharmaceutic adjuvant being applicable to dry powder inhalation as active component and one or more by a kind of Penicillin antibiotics, a kind of glucocorticoid forms Foradil Aerolizer formoterol fumarate, preferred Penicillin antibiotics D90 particle diameter is 1 ~ 10 μm, be preferably 1-7 μm, be more preferably 4 ~ 6 μm.
Above-mentioned pharmaceutic adjuvant contains one or more in carrier, additives.
Above-mentioned carrier is one or more in saccharide, aminoacid, lecithin, phosphatidylcholine, and described aminoacid is one or more in glycine, valine, leucine, and described saccharide is monosaccharide, disaccharide, derived carbohydrate.Described monosaccharide is mannitol, fructose, glucose, described disaccharide is maltose, trehalose, cellobiose, lactose, sucrose, and described derived carbohydrate is eight acetate fiber two sugar esters, sucrose octa-acetate, eight acetic acid lactose esters, five acetic acid glucose esters, six acetic acid Nitranitols and eight acetic acid Sargassum sugar esters.
Above-mentioned carrier can also be one or both the combination in saccharide and lecithin, phosphatidylcholine.
Upper described carrier can also be lactose.Above-mentioned lactose is preferably alpha-lactose monohydrate, β-Lactis Anhydrous, one or more in amorphous spray-dried lactose, crystallizing and drying lactose, Lactis Anhydrous, and preferred lactose is Lactis Anhydrous.
The mean diameter of above-mentioned carrier is 20 ~ 80 μm, and preferred mean diameter is 35 ~ 45 μm.
Above-mentioned additives contain one or more in surfactant, lubricant, antistatic additive.Wherein said surfactant is poloxamer, and described lubricant is one or more in magnesium stearate, micropowder silica gel, Pulvis Talci, and the summation of described active component and the weight ratio of carrier are 1:0.1 ~ 2.
The summation of described active component and the weight ratio of carrier are 1:0.5 ~ 1.
When pharmaceutical composition is Foradil Aerolizer formoterol fumarate, it is characterized in that with single or multiple dosage mode be packed as capsule.
When pharmaceutical composition is aerosol, it is characterized in that the pharmaceutic adjuvant of described aerosol comprises the pharmaceutically useful propellant and other optional additives being applicable to aerosol.Described propellant is one or more in hydrofluoroalkane compounds.Described propellant be preferably in HFA 134a (HFA134a), 1,1,1.2,3,3,3-heptafluoro-propane (HFA 227) one or both.Described propellant is preferably HFA 134a (HFA134a).Comprise solvent in described additives, be selected from glycerol, propylene glycol, Polyethylene Glycol, ethanol or oleic acid.Described solvent is one or more in ethanol, propylene glycol.Described pharmaceutical composition, is characterized in that formula is: the ethanol weight percent content as solvent is 5-50%, and the propellant of surplus.
The application of above-mentioned pharmaceutical composition in preparation treatment asthma, chronic obstructive pneumonia medicine.
The application of above-mentioned pharmaceutical composition in preparation treatment pulmonary infection bacterial drug.
Upper described pharmaceutical composition, is characterized in that the dosage of described Penicillin antibiotics is 0.01-20mg/kg/ days, is preferably 0.5-10mg/kg/ days.
The preparation method of described Foradil Aerolizer formoterol fumarate is: active component, excipient substance are mixed after pulverizing the particle diameter reaching required.
The preparation method of described aerosol is: the active component micropowder adding recipe quantity in aerosol bottle, opens the valve on bottle, is imported by the mixture of the propellant of premixing and optional additives, valve-off, obtain required aerosol by valve.Optional ultra sonic bath is carried out with solubilising to aerosol bottle
Or following preparation method can be adopted: be distributed in additives by micronized active component, then add in the propellant after pre-cooling and mix, then be dispensed in aerosol bottle.
Should be appreciated that because known reason, as the retention of active component in suction apparatus, the amount of often kind of active component that patient sucks can be different from the amount of metering.Therefore the applicating ratio between active component can be different from the ratio of metering.The ratio preferably used is in the described metered proportions indicated.
Described aerosol bottle and valve system can select disclosed aerosol bottle and valve system in Chinese patent CN98805261.X.
Described pharmaceutical composition preparation treatment non-microorganism infect cause asthma, chronic obstructive pulmonary disease medicine in application
In this patent, the dosage of said medicine is with the weighing scale of medicine itself, does not comprise the weight of its salt or ester, and such as penicillin (G) potassium 100mg, in fact refers to penicillin 100mg, instead of the potassium salt 100mg of penicillin.
Particle diameter in the present invention is equivalent volume footpath, is the diameter of the ball identical with actual particle volume.It is generally acknowledged that the diameter that laser method is surveyed is equivalent volume footpath.
Particle diameter corresponding when D90 particle diameter refers to that the cumulative particle sizes distribution number of a sample reaches 90%.Its physical significance be particle diameter be less than it amounts of particles account for 90%, this numerical value can be detected by laser particle instrument.
Mean diameter refers to meso-position radius, can detect with laser particle analyzer.
Detailed description of the invention
Micronization of the present invention can use known mechanical crushing method or spray drying method.Mechanical crushing method refers to and utilizes the method for fluid energy mill (using Nanjing Univ. Instrument Factory QM-3A) respectively medicine and/or carrier powder to be broken into required particle diameter.Spray drying method refers to and medicine and/or carrier is dissolved in organic solvent entirely as in ethanol, through spray dryer (as Buli Minispray, 190 types, Germany or QW-500, Xishan city Lin Zhou drying machine factory), solid material is made required particle diameter.Use during spray drying method and can also add surfactant as poloxamer etc.The process conditions of spray drying method can be: inlet temperature is 105 DEG C, and outlet temperature is 68 DEG C, throughput 90%, and jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Foradil Aerolizer formoterol fumarate adopts No. 3 plant capsules (sino-america joint-venture Suzhou Capsule Co., Ltd produces, trade name: Vcaps), and each embodiment feeds intake according to 1000 capsules.The capsule loading bubble-cap type of Foradil Aerolizer formoterol fumarate is aluminum-plastic packaged, takes out, load inhaler (Shanghai balance pharmaceutical factory) and use during use.
In an embodiment, the combination of following medicine, wherein μ g/ unit refers to administration unit minimum in medicine, and as Foradil Aerolizer formoterol fumarate refers to that μ g/ grain (capsule-type) or μ g/ inhale (multiple dose), aerosol refers to that μ g/ sprays.D90 particle diameter refers to that all medicines in active component 2 are as a sample, particle diameter corresponding when its cumulative particle sizes distribution number reaches 90%, its physical significance be particle diameter be less than it granule account for 90%.
Glucocorticoid medicine (active component 2) uses fluid energy mill micronization, and D90 particle diameter sees the following form:
| Number | Active component 2 | D90 particle diameter (μm) |
| M1-1 | Momestasone furoate | 4.9 |
| M1-2 | Triamcinolone acetonide acetate | 5.2 |
| M1-3 | Ciclesonide | 5.9 |
| M1-4 | Fluticasone propionate | 6.3 |
| M1-5 | Fluticasone furoate | 5.2 |
| M1-6 | Budesonide | 5.4 |
| M1-7 | Beclometasone | 4.7 |
Embodiment 1
According to following table, active component is used fluid energy mill micronization, D90 particle diameter sees the following form, and Lactis Anhydrous 8g fluid energy mill is micronized to mean diameter 36 μm, after mixing, be divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
Embodiment 2
According to following table, active component is used fluid energy mill micronization, D90 particle diameter sees the following form, and Lactis Anhydrous 8g fluid energy mill is micronized to mean diameter 40 μm, after mixing, be divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
Embodiment 3
According to following table, active component is used fluid energy mill micronization, D90 particle diameter sees the following form, and Lactis Anhydrous 8g fluid energy mill is micronized to mean diameter 42 μm, after mixing, be divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
The preparation of aerosol, active component used is the weight of 1000 administration units, and HFA-134a is HFA 134a, and HFA-227 is HFC-227ea.
Embodiment 4
Active component
Ethanol 100g
HFA-227?600g
Preparation technology: the ethanol 1000 times of active ingredient unit weight in following table being added recipe quantity, stirs, divided dose fill, sealing-in dose valve system, and HFA-227 is injected in pressurization more respectively, to obtain final product.
Embodiment 5
According to following table, active component is used fluid energy mill micronization, D90 particle diameter sees the following form, and Lactis Anhydrous 8g fluid energy mill is micronized to mean diameter 42 μm, after mixing, be divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
Embodiment 6
Active component
Ethanol 50g
HFA-134a?600g
Preparation technology: the ethanol 1000 times of active ingredient unit weight in following table being added recipe quantity, stirs, divided dose fill, sealing-in dose valve system, and HFA-134a is injected in pressurization more respectively, to obtain final product.
Embodiment 7
According to following table by active component 1 fluid energy mill micronization, concrete D90 grain diameter value sees the following form, Lactis Anhydrous 8g fluid energy mill micronization, the concrete numerical value of mean diameter sees the following form, after mixing, be divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
Medicine stability test
Matched group is penicillins capsule oral formulation, and concrete condition sees the following form.
Matched group preparation method:
Pulverized by active component in upper table, D90 particle diameter is for seeing the above table, and it is 38-42 μm that ingredient powder is broken into mean diameter, for subsequent use.Active component, adjuvant (low-substituted hydroxypropyl fiber 15g, lactose 10g) to progressively increase method mix homogeneously by equivalent, by above-mentioned mixed-powder 10% starch slurry soft material, cross sieve aperture internal diameter 0.850mm (20 order) sieve series grain, 50 DEG C of aeration-dryings, control moisture 1% ~ 2%, sieve granulate with sieve aperture internal diameter 1.000m m (18 order); In dry granule, add Pulvis Talci, mixing, dress is distributed in 1000 capsules.
Test method:
After embodiment, comparative examples pharmaceutical preparation (date of manufacture is identical) blister package, evenly put, 10/group, with related substance, corresponding thiazole acid (PA) content of a collection of product sampling and measuring medicine, be placed in 60 DEG C of calorstats, place 90 days, in sampling in the 91st day, measure related substance, corresponding thiazole acid (PA) content of medicine.(pharmacy is in progress to see the influence factor of document 1 Penicillin antibiotics stability and determination of related substances method with the above-mentioned concrete method of inspection, 2008, Vol.32, No.2,62) and document 2 liquid chromatograph one MS measure 14 kinds of penicillins and corresponding penicilloic acid residual quantity (assay office, the 31 volume the 9th phase in milk, 67), the difference of twice sampling and measuring numerical value is added up, and the results are shown in following table (mean ± SD, n=10)
High-temperature stability contrast experiment show, compared with oral capsule, be no matter that dry powder sucks capsule, still can the stability of inhalation aerosol all better, especially the amount causing irritated corresponding thiazole acid to increase is compared less, and the stability of two kinds of preparations that this explanation can suck is better.We estimate that this and inhalable formulations in preparation process do not use water relevant, and can the related substance of inhalation aerosol, the recruitment of corresponding thiazole acid has the increase of statistical significance compared with Foradil Aerolizer formoterol fumarate, may be because the existence of ethanol is relevant.
In addition, by the comparison of data between each group, we find in Foradil Aerolizer formoterol fumarate when diameter of aspirin particle is different, the change of total impurities amount is less, there is no statistical significance, but the amount that the acid of corresponding thiazole increases is but obviously different, thus, when penicillin medicine D90 particle diameter as active component is 4 ~ 6 μm, stability is best, and the recruitment of corresponding thiazole acid is less.
Sensitivity test
Laboratory animal: Cavia porcellus, body weight at 250g ± 20g, male and female half and half.According to document oleanolic acid to " anaphylactic shock guinea-pigs " experimental technique preparation in the antagonism (Henan Medical Univ.'s journal, 1996,31 volume the 1st phases, 28) of Penicilloyl protein sensitized guinea pig anaphylactic shock.
Test method: penicillin sensitization Cavia porcellus is divided into embodiment group, comparative examples group (commercially available prod), matched group, each concrete group's laboratory animal is 10, ensure embodiment group simultaneously, (penicillin medicine is commercially available prod to comparative examples group, glucocorticoid medicine is prepared into according to the formula in embodiment 1 and method and can sucks capsule and suck) penicillin medicine in thiazole acid statistical significance on there is no difference, experimental animal medicine is given once a day according to the administering mode (penicillin medicine administration gives glucocorticoid medicine immediately) in following table and dosage (being as the criterion with the dosage of penicillin medicine), shock animals quantity is observed in 2 hours, after epinephrine inj to shock animals subcutaneous injection (SC) 0.05mg/kg with discovery, investigate the dead quantity of shock animals.
Embodiment group result
Comparative examples group:
Note: Neulized inhalation refers to that water for injection put into by medicine, Neulized inhalation (20 minutes).
By above-mentioned experiment, can prove when thiazole acid content is substantially identical, laboratory animal adopts and sucks preparation administration occurs to suffer a shock and suffer a shock compared with oral, the ejection preparation administration quantity of still death after administration and obviously decline, only may with suck that preparation allergin in respiratory tract produces less relevant, and adopt the effect of atomizing type administration poor, mortality of animals is higher, this may be with medicinal atomized process, longer for time of contact with water, air, anaphylaxis material produce add relevant.
Pharmacological Examples 1 asthma pharmacological evaluation
1, animal model
Choose healthy male Wistar rat (there is antibacterial to checking out, the rat of bacteriological infection will not select), body weight is 200 ± 10g, put into the bell glass of about 5 liters, spray into 3% chlorination second phthalein choline and 0.1% histamine phosphate's volume mixed liquor 15 second with the pressure of 400mmHg.After spraying stops, observing the asthmatic latent period (namely asthma occur, breathe be the devil, until twitch time of falling) of rat, draw and breathe heavily the rat that the latent phase is less than 70 seconds or is greater than 120 seconds and will not select.
2, experimental technique
Learn from else's experience and measure the qualified rat of asthmatic latent period, random packet is carried out according to the group in following table, often organize 10, every day carries out administration in the bell glass of about 5 liters, experimental group gives the medicine in embodiment (being as the criterion with the dosage of penicillin medicine) according to inhalation route, model group 1 gives according to inhalation route the Lactis Anhydrous that mean diameter is 40 μm, dosage is 5mg/Kg, matched group gives corresponding dosage matched group medicine according to the route of administration in following table, and (glucocorticoid medicine to be prepared into according to the formula in embodiment 1 and method and can to suck capsule and suck, penicillin medicine administration gives glucocorticoid medicine immediately), successive administration 3 days, within 3rd day, give 0.3% 2 hydrochloric acid histamine when spraying after after giving whole medicine 1.5 hours, observe the change (draw animal when breathing heavily and do not occur in 6 minutes that to breathe heavily the volt phase be calculate for 360 seconds to the person of falling to draw) of asthmatic latent period and tic incidence rate before and after drug.
Dosage in experimental group is as the criterion with penicillin medicine dosage.
3, experimentation and result: animal generation asthma until the time of falling of twitching see the following form.
Have multiple form to be the result of this experiment in the present embodiment, problem for convenience of explanation, splits experimental result.
Matched group experimental result (n=10, mean ± SD)
Matched group illustrates: matched group medicine is the commercially available injection of penicillin medicine or capsule, and concrete using dosage is that 10mg/kg sees the following form.
Rear variant before administration by the asthmatic latent period of testing identity asthmatic model animal by above-mentioned experimental data, can illustrate that asthmatic model animal successively gives penicillins, glucocorticoid medicine, can mild prolonged Paroxysmal asthma, wherein respectively there is 1 mouse generation penicillin anaphylaxis reaction in comparative examples 3-1,3-2 group, cause asthmatic latent period to be less than 10 seconds, related data is disallowable.
The experimental result (n=10, mean ± SD) of penicillin medicine
Can be illustrated by inspection by the experimental data of upper table, penicillin, glucocorticoid compound medicine can play prolongation asthmatic latent period after sucking, reduce the effect of extracting incidence rate out, be significantly improved compared with penicillin, glucocorticosteroidsin in combination medication, irritated probability occur simultaneously and also significantly declines.
Pharmacological Examples 2 pulmonary inflammation model pharmacological evaluation
1, pneumonia animal model:
SD rat, male and female dual-purpose, Mus age 8 week age, body weight 150 ~ 170g.Release the bacterium liquid that escherichia coli reference culture is mixed with 0.5 Maxwell concentration, anesthetized rat, cervical region sterilization, preserved skin, exposed Rats upper trachea, instillation 0.2ml bacterium liquid, makes the model that rat lung infects escherichia coli.
2, experimental technique
Get the rat model of above-mentioned infection escherichia coli, random packet is carried out according to the group in following table, often organize 20, each group for the treatment of time started is for infecting 24h, administration time is 3 days, blank group 1, embodiment group carries out administration every day in the bell glass of about 5 liters, embodiment group gives the medicine in embodiment according to inhalation route, blank group 1 gives according to inhalation route the Lactis Anhydrous that mean diameter is 40 μm, dosage is 5mg/Kg, matched group (glucocorticoid medicine is prepared into according to the formula in embodiment 1 and method and can sucks capsule and suck) gives corresponding dosage comparative examples group medicine (penicillin medicine is commercially available) according to the route of administration (penicillin medicine administration gives glucocorticoid medicine immediately) in following table, blank 2 groups give water for injection 0.5ml, 3rd day when measuring lung homogenate bacteria cultivation results in the following way after after giving whole medicine 8 hours.
3, experimentation and result: the 3rd day when the urethane execution of after after giving whole medicine 8 hours, rat being injected fatal dose, open rapidly thoracic cavity and isolate lung tissue, put into tissue grinder and make lung homogenate under 4 DEG C of ice baths, successively homogenate 0. 1ml is spread evenly across on agar plate, the flat board coated is put into 35 DEG C of incubators and hatch 24h, detect, calculate the negative quantity of corresponding bacteria cultivation results, as animal generation death condition in three days, measure corresponding bacteria cultivation results according to the method described above immediately, and calculate negative according to testing result, positive quantity.
Have multiple form to be the result of this experiment in the present embodiment, problem for convenience of explanation, splits experimental result.
Matched group experimental result (n=20)
The experimental result (n=20) of penicillin medicine
| Embodiment number | Route of administration | Dosage (mg/kg) | Negative (only) | Positive (only) |
| 1-1 | Oral cavity sucks | 10 | 10 | 10 |
| 1-3 | Oral cavity sucks | 10 | 11 | 9 |
| 1-5 | Oral cavity sucks | 10 | 11 | 9 |
| 1-6 | Oral cavity sucks | 10 | 12 | 8 |
| 1-7 | Oral cavity sucks | 10 | 12 | 8 |
| 1-8 | Oral cavity sucks | 10 | 11 | 9 |
| 1-11 | Oral cavity sucks | 10 | 13 | 7 |
| 1-13 | Oral cavity sucks | 10 | 13 | 7 |
| 4-1 | Oral cavity sucks | 10 | 9 | 11 |
| 4-5 | Oral cavity sucks | 10 | 9 | 11 |
| 4-7 | Oral cavity sucks | 10 | 10 | 10 |
| 6-8 | Oral cavity sucks | 10 | 10 | 10 |
| 6-11 | Oral cavity sucks | 10 | 9 | 11 |
| 6-13 | Oral cavity sucks | 10 | 10 | 10 |
| 5-1 | Oral cavity sucks | 10 | 13 | 7 |
| 5-2 | Oral cavity sucks | 10 | 14 | 6 |
| 5-3 | Oral cavity sucks | 10 | 13 | 7 |
| 5-4 | Oral cavity sucks | 10 | 13 | 7 |
| 5-5 | Oral cavity sucks | 10 | 12 | 8 |
| 5-6 | Oral cavity sucks | 10 | 13 | 7 |
| Blank 1 group | Oral cavity sucks | 0 | 20 |
By above-mentioned experimental data, prove to suck preparation under Isodose and suppress the effect of pneumococcal bacteria significantly better than injection and oral.
Claims (10)
1. an inhalable drug compositions, is characterized in that the pharmaceutic adjuvant being applicable to inhalation as active component and one or more by a kind of Penicillin antibiotics, a kind of glucocorticoid forms.
2. pharmaceutical composition as claimed in claim 1, is characterized in that described Penicillin antibiotics is one or more in penicillin (G), procaine benzylpenicillin, benzathine benzylpenicillin, penicillin V (penicillin Vl phenoxymethylpenicillin), oxazacillin, cloxacillin, ampicillin, amoxicillin, piperacillin, azlocillin, mezlocillin, aspoxicillin and pharmaceutically useful salt thereof.
3. pharmaceutical composition as claimed in claim 1, is characterized in that described glucocorticoid is one or more in ciclesonide, fluticasone, mometasone, budesonide, beclometasone, triamcinolone acetonide, methylprednisolone, triamcinolone, hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone or its ester, salt.
4. inhalable drug compositions as claimed in claim 1, is characterized in that described pharmaceutical composition is Foradil Aerolizer formoterol fumarate or aerosol.
5. pharmaceutical composition as claimed in claim 1, is characterized in that described pharmaceutical composition is that the pharmaceutic adjuvant being applicable to dry powder inhalation as active component and one or more by a kind of Penicillin antibiotics, a kind of glucocorticoid forms Foradil Aerolizer formoterol fumarate.
6. pharmaceutical composition as claimed in claim 6, is characterized in that one or more that described pharmaceutic adjuvant contains in carrier, additives.
7. pharmaceutical composition as claimed in claim 12, is characterized in that described carrier is one or more in saccharide, aminoacid, lecithin, phosphatidylcholine.
8. pharmaceutical composition as claimed in claim 4, is characterized in that the pharmaceutic adjuvant of described aerosol comprises the pharmaceutically useful propellant and other optional additives being applicable to aerosol.
9. the application of pharmaceutical composition according to claim 1 in preparation treatment asthma, chronic obstructive pneumonia medicine.
10. the application of pharmaceutical composition according to claim 1 in preparation treatment pulmonary infection bacterial drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310205574.8A CN104208045A (en) | 2013-05-29 | 2013-05-29 | Compound inhalation preparation containing penicillin antibiotic and glucocorticoid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310205574.8A CN104208045A (en) | 2013-05-29 | 2013-05-29 | Compound inhalation preparation containing penicillin antibiotic and glucocorticoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104208045A true CN104208045A (en) | 2014-12-17 |
Family
ID=52090223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310205574.8A Pending CN104208045A (en) | 2013-05-29 | 2013-05-29 | Compound inhalation preparation containing penicillin antibiotic and glucocorticoid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208045A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587481A (en) * | 2020-12-28 | 2021-04-02 | 成都中牧生物药业有限公司 | Alkalescent amoxicillin soluble powder and preparation method thereof |
| CN114796116A (en) * | 2022-05-17 | 2022-07-29 | 中山大学附属第六医院 | Azithromycin inhalant and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1439360A (en) * | 2003-03-07 | 2003-09-03 | 南昌弘益科技有限公司 | Dry powder composition for improvement of effective position medical deposit |
| CN101756942A (en) * | 2008-12-25 | 2010-06-30 | 天津金耀集团有限公司 | Oral lung inhalation aerosol powder |
| CN102395356A (en) * | 2009-02-18 | 2012-03-28 | 阿拉迪姆公司 | Ph-modulated formulations for pulmonary delivery |
-
2013
- 2013-05-29 CN CN201310205574.8A patent/CN104208045A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1439360A (en) * | 2003-03-07 | 2003-09-03 | 南昌弘益科技有限公司 | Dry powder composition for improvement of effective position medical deposit |
| CN101756942A (en) * | 2008-12-25 | 2010-06-30 | 天津金耀集团有限公司 | Oral lung inhalation aerosol powder |
| CN102395356A (en) * | 2009-02-18 | 2012-03-28 | 阿拉迪姆公司 | Ph-modulated formulations for pulmonary delivery |
Non-Patent Citations (4)
| Title |
|---|
| 刘国祥: "支气管哮喘合并感染的治疗问题", 《新医学》 * |
| 崔福德: "《药剂学》", 31 January 2006, 中国医药科技出版社 * |
| 王学民: "《生物药物制剂技术》", 30 September 2010, 化学工业出版社 * |
| 贺明等: "156例支气管哮喘急性发作期致病菌药敏分析", 《实用医技杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587481A (en) * | 2020-12-28 | 2021-04-02 | 成都中牧生物药业有限公司 | Alkalescent amoxicillin soluble powder and preparation method thereof |
| CN114796116A (en) * | 2022-05-17 | 2022-07-29 | 中山大学附属第六医院 | Azithromycin inhalant and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104208076A (en) | Compound inhalation preparation containing cephalosporin antibiotic and glucocorticoid | |
| WO2021229514A1 (en) | Pharmaceutical ivermectin compositions | |
| CN105101955A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| EP4125804A1 (en) | Treatment | |
| CN104208043A (en) | Inhalation preparation containing cephalosporin antibiotic | |
| TW200524615A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| AU2015261103A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD | |
| CN104208045A (en) | Compound inhalation preparation containing penicillin antibiotic and glucocorticoid | |
| JP6919093B2 (en) | A composition comprising at least one dry powder obtained by spray drying to enhance the stability of the formulation. | |
| CN104208701A (en) | Compound inhalation preparation containing antifungal drug | |
| CN104208060A (en) | Compound inhalation preparation containing penicillin antibiotic | |
| ITMI20130571A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL | |
| CN104208687A (en) | Dry powder inhalation pharmaceutical composition containing different active components packaged in inhalation device for synchronous application | |
| CN104208688A (en) | Pharmaceutical composition containing individually-packaged mometasone furoate and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208690A (en) | Pharmaceutical composition containing individually-packaged ciclesonide and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208075A (en) | Compound inhalation preparation containing carbapenem antibiotic and glucocorticoid | |
| CN104758294A (en) | Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof | |
| CN103830208A (en) | H1-receptor-antagonist-containing inhalation preparation | |
| CA2456721C (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| CN103127133A (en) | Inhalation drug composition with fluticasone propionate and nitric oxide synthase (NOS) inhibitor | |
| CN104208689A (en) | Pharmaceutical composition containing individually-packaged budesonide and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208686A (en) | Pharmaceutical composition containing individually-packaged fluticasone and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208046A (en) | Carbapenem antibiotic inhalation preparation | |
| CN117205186A (en) | Leifenacin inhalation spray and preparation method thereof | |
| WO2022166724A1 (en) | Fudosteine solution preparation for inhalation, preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141217 |
|
| WD01 | Invention patent application deemed withdrawn after publication |